Thromboembolic complications of sepsis: what is the incidence and pathophysiological mechanisms involved?

Thromb Haemost. 2008 May;99(5):801-2. doi: 10.1160/TH08-03-0192.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Acute Coronary Syndrome / etiology
  • Anti-Infective Agents / therapeutic use
  • Arterial Occlusive Diseases / etiology*
  • Arterial Occlusive Diseases / physiopathology
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Incidence
  • Phospholipases A2, Secretory / antagonists & inhibitors
  • Protein C / therapeutic use
  • Recombinant Proteins / therapeutic use
  • Sepsis / complications*
  • Sepsis / drug therapy
  • Sepsis / physiopathology
  • Severity of Illness Index
  • Stroke / etiology
  • Thromboembolism / etiology*
  • Thromboembolism / physiopathology
  • Thromboembolism / prevention & control
  • Time Factors
  • Venous Thromboembolism / etiology*
  • Venous Thromboembolism / physiopathology

Substances

  • Anti-Infective Agents
  • Enzyme Inhibitors
  • Protein C
  • Recombinant Proteins
  • Phospholipases A2, Secretory
  • drotrecogin alfa activated